3-O-Sulfogalactosylceramide (d18:1/22:0)
|
Basic information |
| Metabolite name | 3-O-Sulfogalactosylceramide (d18:1/22:0) |
 | HMDB0012316 |
 |
C06125 |
 |
24779582 |
| Synonyms | SL d18:1/22:0 |
| No. of studies | 3 |
|
Basic information |
| Metabolite name | 3-O-Sulfogalactosylceramide (d18:1/22:0) |
| HMDB0012316 |
|
C06125 |
|
24779582 |
| Synonyms | SL d18:1/22:0 |
| No. of studies | 3 |
|
Relationship between 3-O-Sulfogalactosylceramide (d18:1/22:0) and depression (count: 3) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1072 | Type1 | CUMS group vs. control group | Amygdala | Cynomolgus monkey | Down |
| Study M123 | Type3 | rTMS group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M123 | Type3 | rTMS group vs. control group | Striatum | Wistar rat | Down |
| Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M457 | Type2 | CUMS + D6 doses of PBR group vs. CUMS group | Serum | Sprague-Dawley rat | Down |